Why Are We Targeting NDM1?

Photo Credit: Peter Hellberg

NDM-1 is a dimetallo-beta-lactamase capable of deactivating the most commonly administered antibiotics, gaining international attention for this enzyme as a clinically-relevant pharmaceutical target, yet drug development efforts have proven ineffective due to a lack of effective inhibitors.  Efforts in our lab to selectively target dimetalloenzymes has led to the discovery of compounds that are the most potent inhibitors of NDM-1 to date.